IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit ...

Royalty Pharma (NASDAQ:RPRX) executives highlighted what they described as a “landmark year” in 2025, pointing to ...

Q4 2025 earnings call recap: 2026 guidance, royalty receipts growth outlook, synthetic royalty deals, pipeline catalysts, and ...

The loss of market exclusivity for a trio of big-selling drugs in the last quarter of 2025 dragged down Novartis sales, but chief executive Vas Narasimhan says the company is equipped to ride out "the ...

Novartis CEO Vas Narasimhan saw his realized compensation swell by 30% in 2025, reaching 24.9 million Swiss francs ($32.4 million) as the Swiss pharma giant exceeded its long-term financial and ...

The pharma major said it faces the largest drug-patent expiry headwind in its history this year.

Swiss pharma giant Novartis AG NVS reported fourth-quarter core earnings per share (excluding one-time charges) of $2.03, which beat the Zacks Consensus Estimate of $1.99. The figure was also up from ...

Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2025 and introduced full year 2026 guidance for Portfolio Receipts.

Swiss pharmaceutical Novartis AG (NYSE: NVS) reported fourth-quarter 2025 results on Wednesday. The company's net sales rose 1% year over year to $13.34 billion, missing Wall Street's consensus ...

Sweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover of Dova Pharmaceuticals. The deal – valued at up to $915 million – is due to ...